دورية أكاديمية
أعرض في EDS

Synergistic effects of the sesquiterpene lactone, EPD, with cisplatin and paclitaxel in ovarian cancer cells.

التفاصيل البيبلوغرافية
العنوان: Synergistic effects of the sesquiterpene lactone, EPD, with cisplatin and paclitaxel in ovarian cancer cells.
المؤلفون: van Haaften C; Department of Gynecology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. carocell@planet.nl., Boot A; Department of Pathology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. A.Boot@lumc.nl., Corver WE; Department of Pathology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. W.E.Corver@lumc.nl., van Eendenburg JD; Department of Pathology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. J.D.H.van_Eendenburg@lumc.nl., Trimbos BJ; Department of Gynecology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. J.B.M.Z.Trimbos@lumc.nl., van Wezel T; Department of Pathology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. T.van_Wezel@lumc.nl.
المصدر: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2015 Apr 25; Vol. 34, pp. 38. Date of Electronic Publication: 2015 Apr 25.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 8308647 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-9966 (Electronic) Linking ISSN: 03929078 NLM ISO Abbreviation: J Exp Clin Cancer Res Subsets: MEDLINE
أسماء مطبوعة: Publication: 2009- : London : BioMed Central
Original Publication: [Roma] : APSIT,
مواضيع طبية MeSH: Antineoplastic Agents/*therapeutic use , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Lactones/*therapeutic use , Ovarian Neoplasms/*drug therapy , Sesquiterpenes/*pharmacology, Antineoplastic Agents/administration & dosage ; Cell Line, Tumor ; Cisplatin/pharmacology ; Drug Synergism ; Female ; Humans ; Ovarian Neoplasms/pathology ; Paclitaxel/pharmacology
مستخلص: Background: Ovarian cancer remains still the leading cause of death of gynecological malignancy, in spite of first-line chemotherapy with cisplatin and paclitaxel. Although initial response is favorably, relapses are common and prognosis for women with advanced disease stays poor. Therefore efficacious approaches are needed.
Methods: Previously, an anti-cancer agent, EPD exhibited potent cytotoxic effects towards ovarian cancer and not towards normal cells. Cell viability and cell cycle analysis studies were performed with EPD, in combination with cisplatin and/or paclitaxel, using the ovarian carcinoma cell lines: SK-OV-3, OVCAR-3, JC, JC-pl and normal fibroblasts. Cell viability was measured using Presto Blue and cell cycle analysis using a flow cytometer. Apoptosis was measured in JC and JC-pl , using the caspase 3 assay kit.
Results: In JC-pl, SK-OV-3 and JC, synergistic interactions between either EPD and cisplatin or EPD and paclitaxel were observed. For the first time the effects of EPD on the cell cycle of ovarian cancer cells and normal cells was studied. EPD and combinations of EPD with cisplatin and/ or paclitaxel showed cell cycle arrest in the G2/M phase. The combination of EPD and cisplatin showed a significant synergistic effect in cell line JC-pl, while EPD with paclitaxel showed synergistic interaction in JC. Additionally, synergistic drug combinations showed increased apoptosis.
Conclusions: Our results showed a synergistic effect of EPD and cisplatin in an ovarian drug resistant cell line as well as a synergistic effect of EPD and paclitaxel in two other ovarian cell lines. These results might enhance clinical efficacy, compared to the existing regimen of paclitaxel and cisplatin.
References: Eur J Cancer. 1995;31A(1):92-7. (PMID: 7695986)
Gynecol Oncol. 1997 Apr;65(1):13-22. (PMID: 9103385)
Acta Pharmacol Sin. 2015 Apr;36(4):507-16. (PMID: 25619393)
Cancer Res. 2006 Oct 1;66(19):9339-44. (PMID: 16990346)
Drug Discov Today. 2010 Aug;15(15-16):668-78. (PMID: 20541036)
Anticancer Drugs. 2012 Oct;23(9):883-96. (PMID: 22797176)
Prostate. 2009 Jun 1;69(8):827-37. (PMID: 19204913)
Cell Death Differ. 1999 Feb;6(2):99-104. (PMID: 10200555)
Cancer Res. 2008 Jun 1;68(11):4311-20. (PMID: 18519691)
Cell Cycle. 2008 May 15;7(10):1360-70. (PMID: 18418062)
J Exp Clin Cancer Res. 2013;32:48. (PMID: 23902592)
Mol Cell Biochem. 2012 Apr;363(1-2):257-68. (PMID: 22160925)
J Clin Oncol. 1999 Jul;17(7):2069-80. (PMID: 10561260)
Anticancer Agents Med Chem. 2007 Jan;7(1):3-18. (PMID: 17266502)
Asian Pac J Cancer Prev. 2015;16(3):863-8. (PMID: 25735374)
J Exp Clin Cancer Res. 2011;30:87. (PMID: 21943236)
Curr Med Chem Anticancer Agents. 2005 May;5(3):239-49. (PMID: 15992352)
Med Oncol. 2012 Dec;29(5):3400-8. (PMID: 22638913)
Cancer Cell Int. 2013 Jul 30;13(1):77. (PMID: 23899403)
Gynecol Oncol. 2005 Jul;98(1):141-5. (PMID: 15963813)
Br J Cancer. 1994 Feb;69(2):299-306. (PMID: 7905279)
Cancer Res. 1983 Aug;43(8):3725-31. (PMID: 6861142)
J Exp Clin Cancer Res. 2011;30:29. (PMID: 21401934)
Mol Cancer Ther. 2012 Apr;11(4):1026-35. (PMID: 22302098)
Nat Rev Cancer. 2011 Oct;11(10):719-25. (PMID: 21941283)
المشرفين على المادة: 0 (Antineoplastic Agents)
0 (Lactones)
0 (Sesquiterpenes)
P88XT4IS4D (Paclitaxel)
Q20Q21Q62J (Cisplatin)
تواريخ الأحداث: Date Created: 20150425 Date Completed: 20160413 Latest Revision: 20181113
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC4472250
DOI: 10.1186/s13046-015-0157-2
PMID: 25907439
قاعدة البيانات: MEDLINE
الوصف
تدمد:1756-9966
DOI:10.1186/s13046-015-0157-2